Product Wiki · Recalls · Health Canada Consumer Product Safety

Recall 24287 — Association of Raptiva (efalizumab) with serious infections, including progressive multifocal leukoencephalopathy in patients with psoriasis - For Health Professionals

Health Canada Consumer Product Safety · Canada · 2008-12-30

AI-assisted, human-edited — this page is drafted with AI from public-source data, then reviewed before publication. How we use AI →
Agency
Health Canada Consumer Product Safety
Recall identifier
24287
Date of alert
2008-12-30
Country / jurisdiction
Canada
Risk type
recall
Product category
Biologic or vaccine
Product type
Marketed health products
Primary source: https://recalls-rappels.canada.ca/en/alert-recall/association-raptiva-efalizumab

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

Related

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.